2022 China Biopharmaceutical Equipment Industry Research Report (with report)

Summary

The development prospects of biopharmaceutical equipment are closely related to downstream application fields. From the perspective of drug segments, China’s biological drug market can be mainly divided into blood products, recombinant proteins, monoclonal antibodies and vaccines.

The field with the most application of monoclonal antibody drugs is tumor treatment. In 2020, the number of cancer deaths in China will be 3 million, accounting for 30% of the total number of cancer deaths in the world. The total size of the product industry is about 54 billion yuan. Based on the average usage level of developed countries, China’s blood products industry has more than double the growth space; China’s vaccine industry is expected to reach 206.5 billion yuan in 2025 and 383.5 billion yuan in 2031. , the CAGR from 2021 to 2025 is 20.0%, and the CAGR from 2026 to 2031 is 10.7%; China’s CGT industry started later than developed countries such as Europe and the United States, but it is developing rapidly. It is expected that the domestic CGT market will grow in 2021-2025 The annual CAGR is expected to reach 183.7%, and the market size is expected to be US$2.59 billion in 2025.

Favorable industrial policies related to biopharmaceuticals and biopharmaceutical equipment have created a favorable external environment for the development of the biopharmaceutical equipment industry. Currently, biopharmaceutical industry clusters including Guangdong, Hong Kong and Macao are developing rapidly, and with policy support, it is expected to further increase regional concentration. , improve the layout of the industrial chain and supply chain, and have broad development space for domestic biopharmaceutical equipment enterprises.

Blood products and recombinant proteins are important downstream areas

From the perspective of drug segments, China’s biopharmaceutical market can be mainly divided into blood products, recombinant proteins, monoclonal antibodies and vaccines. Among them, blood products and recombinant proteins have maintained a relatively high market share in recent years due to the relatively mature market development, accounting for 14% and 13% respectively.

The blood products industry has considerable development prospects

Compared with developed countries, except that human albumin exceeds the average level of developed countries, the per capita consumption of other types of blood products in China is generally small, the per capita consumption of human immunoglobulin is only 10% of that of developed countries in Europe and the United States, and the per capita consumption of coagulation factor 8 is relatively small. Consumption is only 1.6% of developed countries. In 2020, the total scale of China’s blood products industry is about 54 billion yuan. Based on the average usage level of developed countries, China’s blood products industry has more than double the growth space.

High-end pharmaceutical equipment is in line with the direction of national industrial development encouragement

The “Industrial Structure Adjustment Guidance Catalog” and the “14th Five-Year Plan for the Development of the Pharmaceutical Industry” and other industrial plans encourage the development of high-end pharmaceutical equipment at the national top-level design level, encourage the realization of domestic substitution, and ensure the stability of my country’s industrial chain and supply chain.

Industrial clusters effectively promote the development of the biopharmaceutical equipment industry

At present, my country’s biopharmaceutical industry is forming three major industrial clusters of Beijing-Tianjin-Hebei, Yangtze River Delta and Guangdong, Hong Kong and Macao. The overall regional concentration is relatively high. In the future, with the development of industrial policies and the release of market demand, the industrial concentration in the region is expected to further improve. The chain industry chain is improving day by day, which will further stimulate the development of biopharmaceutical equipment.

To view the full report click here

Note: Unless it is marked as original, it is all submitted by netizens or institutions for sharing. If you need to publish, please contact [email protected].

This article is reprinted from: https://www.dx2025.com/archives/172907.html
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment